페이로니병의 치료에서 Potassium Aminobenzoate의 초기 경험
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 함병국 | - |
dc.contributor.author | 문두건 | - |
dc.contributor.author | 박종진 | - |
dc.contributor.author | 노태일 | - |
dc.contributor.author | 김상우 | - |
dc.contributor.author | 박태용 | - |
dc.contributor.author | 안순태 | - |
dc.contributor.author | 오미미 | - |
dc.date.accessioned | 2021-09-07T19:00:46Z | - |
dc.date.available | 2021-09-07T19:00:46Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 2287-4208 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/114183 | - |
dc.description.abstract | Purpose: To evaluate the effect and improvement of potassium aminobenzoate (500 mg Peyron capsule) in oral therapy for Peyronie’s disease. Materials and Methods: From February 2011 to September 2011, 31 patients with Peyronie’s disease received potassium aminobezoate (500 mg Peyron capsules) and were divided into two groups. Group 1 (N=10) received potassium aminobezoate (500 mg Peyron capsule) 3 g four times daily without previous treatment of Peyronie’s disease, while group 2 (N=21) received the same drug with previous treatment of Peyronie’s disease (10 mg Tamoxifen+300 mg L-carnitine two times daily). Outcomes were assessed by subjective symptom change, pain relief, resolutions of the plaque, and curvature. Results: After 3 months, there were no significant improvements in clinical outcomes of either group and among all the patients, 23 stopped taking potassium aminobezoate (23/31, 74%). The reasons for ceasing the therapy were gastrointestinal trouble (8/23, 35%), too many doses to take (7/23, 30%), ineffectiveness (6/23, 26%), and high price (2/23, 9%). Conclusions: Athough the etiology of Peyronie’s disease has not been elucidated, potassium aminobenzoate in therapy of Peyronie’s disease has been used. The use of this medication has the limitations of gastrointestinal trouble, ineffectiveness, too many doses, and high price. Further evaluations of the effect and appropriate dosing of potassium aminobenzoate are needed. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | 대한남성과학회 | - |
dc.title | 페이로니병의 치료에서 Potassium Aminobenzoate의 초기 경험 | - |
dc.title.alternative | Effect of Potassium Aminobezoate in Oral Therapy for Peyronie’s Disease: Preliminary Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 문두건 | - |
dc.contributor.affiliatedAuthor | 오미미 | - |
dc.identifier.bibliographicCitation | The World Journal of Men's Health, v.29, no.3, pp.213 - 217 | - |
dc.relation.isPartOf | The World Journal of Men's Health | - |
dc.citation.title | The World Journal of Men's Health | - |
dc.citation.volume | 29 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 213 | - |
dc.citation.endPage | 217 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001614071 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Penile | - |
dc.subject.keywordAuthor | Induration | - |
dc.subject.keywordAuthor | 4-aminobenzoic acid | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.